TY - JOUR
T1 - AEG-1 promoter-mediated imaging of prostate cancer
AU - Bhatnagar, Akrita
AU - Wang, Yuchuan
AU - Mease, Ronnie C.
AU - Gabrielson, Matthew
AU - Sysa, Polina
AU - Minn, Il
AU - Green, Gilbert
AU - Simmons, Brian
AU - Gabrielson, Kathleen
AU - Sarkar, Siddik
AU - Fisher, Paul B.
AU - Pomper, Martin G.
PY - 2014/10/15
Y1 - 2014/10/15
N2 - We describe a new imaging method for detecting prostate cancer, whether localized or disseminated and metastatic to soft tissues and bone. The method relies on the use of imaging reporter genes under the control of the promoter of AEG-1 (MTDH), which is selectively active only in malignant cells. Through a systemic, nanoparticle-based delivery of the imaging construct, lesions can be identified through bioluminescence imaging and single-photon emission computed tomography in the PC3-ML murine model of prostate cancer at high sensitivity. This approach is applicable for the detection of prostate cancer metastases, including bone lesions for which there is no current reliable agent for noninvasive clinical imaging. Furthermore, the approach compares favorably with accepted and emerging clinical standards, including PET with [18F]fluorodeoxyglucose and [18F]sodium fluoride. Our results offer a preclinical proof of concept that rationalizes clinical evaluation in patients with advanced prostate cancer.
AB - We describe a new imaging method for detecting prostate cancer, whether localized or disseminated and metastatic to soft tissues and bone. The method relies on the use of imaging reporter genes under the control of the promoter of AEG-1 (MTDH), which is selectively active only in malignant cells. Through a systemic, nanoparticle-based delivery of the imaging construct, lesions can be identified through bioluminescence imaging and single-photon emission computed tomography in the PC3-ML murine model of prostate cancer at high sensitivity. This approach is applicable for the detection of prostate cancer metastases, including bone lesions for which there is no current reliable agent for noninvasive clinical imaging. Furthermore, the approach compares favorably with accepted and emerging clinical standards, including PET with [18F]fluorodeoxyglucose and [18F]sodium fluoride. Our results offer a preclinical proof of concept that rationalizes clinical evaluation in patients with advanced prostate cancer.
UR - http://www.scopus.com/inward/record.url?scp=84908146948&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84908146948&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-14-0018
DO - 10.1158/0008-5472.CAN-14-0018
M3 - Article
C2 - 25145668
AN - SCOPUS:84908146948
VL - 74
SP - 5772
EP - 5781
JO - Cancer Research
JF - Cancer Research
SN - 0008-5472
IS - 20
ER -